#	Pagina
attuale pagina	/open-h2020/projects/195560/index.html
-1	/open-fp7/projects/96766/index.html

Opendata, web and dolomites

breast cancer dormancy

Molecular characterisation of a clinical model of estrogen receptor-positive breast cancer dormancy

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

breast cancer dormancy project word cloud

Explore the words cloud of the breast cancer dormancy project. It provides you a very rough idea of what is the project "breast cancer dormancy" about.

neoadjuvant excised diagnosis continues dormancy previously recurrence receptor weeks molecular exposure first proteome letrozole technologies receive estrogen quality extend stable utilising model survival accordance incidence preventing resistance alpha positive analysed minority breast combines months size characterise received training academic data steady performed rate tumour cumulative tumours introducing majority genome er society cells therapy valuable integrative opportunity fellow biopsies competence generally series individualized treatment time clinical bioinformatics endocrine dormant post life profiles continue profiling suppression cancer patients outcomes extended death genomics economy expression metastasis window multidisciplinary throughput dynamic

Project "breast cancer dormancy" data sheet

The following table provides information about the project.

Coordinator	THE UNIVERSITY OF EDINBURGH Organization address address: OLD COLLEGE, SOUTH BRIDGE city: EDINBURGH postcode: EH8 9YL website: www.ed.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	https://www.researchgate.net/project/Breast-cancer-dormancy
Total cost	195˙454 €
EC max contribution	195˙454 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2014
Funding Scheme	MSCA-IF-EF-ST
Starting year	2015
Duration (year-month-day)	from 2015-09-01 to 2017-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	THE UNIVERSITY OF EDINBURGH THE UNIVERSITY OF EDINBURGH Organization address address: OLD COLLEGE, SOUTH BRIDGE city: EDINBURGH postcode: EH8 9YL website: www.ed.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (EDINBURGH)	coordinator	195˙454.00

Map

Project objective

'Endocrine therapy has clearly improved outcomes for estrogen receptor alpha positive (ER) breast cancer patients, however the cumulative incidence of recurrence and death continues at a steady rate . The majority of ER breast tumours treated with neoadjuvant letrozole in respond quickly and are generally excised after three months. A minority of tumours maintain a stable size by becoming dormant, these tumours continue to receive extended letrozole treatment and therefore represent the best currently available clinical model to investigate dormancy. We have previously performed a number of dynamic molecular studies of cancer treatment by taking pre- and post-treatment tumour biopsies utilising the 'window of opportunity'. In this study, for the first time, the dormant cancer cells from breast tumour biopsies that have received extended (1-3 years) neoadjuvant endocrine therapy will be studied. This study aims to characterise the ER breast cancer dormancy and letrozole resistance using expression profiling technologies of this unique series of breast tumour biopsies. The genome- and proteome-wide expression data will be analysed and compared with data for the same patients at diagnosis, at two weeks and at three months following treatment and with the clinical outcomes. Our study will be the first to characterise extended growth suppression in letrozole-treated dormant-state breast cancer. This knowledge will be very valuable to extend ER breast cancer patients' survival and quality of life by preventing metastasis and also contribute to the economy and society by introducing a individualized therapy that is tailored in accordance with cancer patients’ expression profiles. This multidisciplinary project combines both clinical and academic aspects along with exposure to the non-academic sector, in order to provide the fellow with great competence in cancer genomics through training in advanced integrative bioinformatics analysis of high-throughput data.'

Publications

List of publications.
year	authors and title	journal	last update
2016	Cigdem Selli, Arran K. Turnbull, Renshaw L., Thomas J.S., J. Michael Dixon, Andrew H. Sims UK Breast Cancer Research Symposium 2016: Submitted Abstracts published pages: 177-197, ISSN: 0167-6806, DOI: 10.1007/s10549-016-3898-5	Breast Cancer Research and Treatment 159/1	2019-06-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREAST CANCER DORMANCY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BREAST CANCER DORMANCY" are provided by the European Opendata Portal: CORDIS opendata.